SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: TobagoJack who wrote (140038)3/16/2018 6:09:38 AM
From: THE ANT  Read Replies (2) | Respond to of 220545
 
SRPT position should be increased. 3 gene therapies for DMD in progress with incredible results in animal models with great safety. They plan to start an entire gene therapy division for multiple genetic illnesses if results are positive. Their science is incredible. In biotech follow the science. Only Janet Woodcock at the FDA could see the science through the corruption of the system



To: TobagoJack who wrote (140038)3/16/2018 4:10:44 PM
From: John Pitera  Read Replies (1) | Respond to of 220545
 
Hi TB,

I have not seen Martin Armstrong's thinking on the "slightest-shot".... do you have a link....... or a
thumbnail summary?

many thanks,

John


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News